Viking Therapeutics to Present at 22nd Annual Needham Healthcare Conference

Rhea-AI Summary

On April 11, 2023, Viking Therapeutics (NASDAQ: VKTX) announced that its CEO, Brian Lian, Ph.D., will present at the 22nd Annual Needham Healthcare Conference. The conference is scheduled for April 17-20, 2023, with Viking's presentation set for 10:15 a.m. Eastern on April 18, 2023. This virtual event will feature corporate presentations and one-on-one meetings between management and investors.

Viking Therapeutics specializes in developing novel therapies for metabolic and endocrine disorders, with three compounds under clinical trials. Notable projects include VK2809, targeting non-alcoholic steatohepatitis (NASH) and VK2735, aimed at metabolic disorders. The company’s expertise in metabolism drives its innovative therapeutic approach.

SAN DIEGO, April 11, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the 22^nd Annual Needham Healthcare Conference. The conference will take place April 17-20, 2023.

Details for this presentation are as follows:

• 22^nd Annual Needham Healthcare Conference
  Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings
  Conference Dates: April 17-20, 2023
  Presentation Timing: 10:15 a.m. Eastern on Tuesday, April 18, 2023
  Format: Virtual conference

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. VK2735 is currently being evaluated in a Phase 1 clinical trial. In the rare disease space, the company is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-22nd-annual-needham-healthcare-conference-301793723.html

SOURCE Viking Therapeutics, Inc.

FAQ

What is the date of Viking Therapeutics' presentation at the Needham Healthcare Conference?

Viking Therapeutics will present on April 18, 2023, at 10:15 a.m. Eastern.

Where is the 22nd Annual Needham Healthcare Conference being held?

The conference will be held virtually from April 17-20, 2023.

What is Viking Therapeutics focusing on in its clinical trials?

Viking Therapeutics is focusing on developing therapies for metabolic and endocrine disorders.

What compounds is Viking Therapeutics currently developing?

Viking is developing VK2809 for NASH and VK2735 for metabolic disorders, among others.

What is the primary indication for VK2809?

VK2809 is being evaluated for treating non-alcoholic steatohepatitis (NASH) and fibrosis.